10 Best Growth Stocks To Buy Now According To Billionaire Ray Dalio
Ray Dalio is one of the most successful investors in Wall Street's history.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Neo Ivy Capital Renee Yao | 25,660 | $2,909 | 0.57% | |
| 2. | 0 | $0 | -100% | 0% | |
| 3. | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | Director | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | Director | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | Director | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | Director | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | Director | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $114.29 | 659 | Officer | 66,901 | 2024-06-28 | Filing | |
| $117.25 | 299 | Director | 56,398 | 2024-06-18 | Filing | |
| $116.75 | 3,007 | Director | 56,697 | 2024-06-18 | Filing | |
| $117.77 | 475 | Director | 59,704 | 2024-06-17 | Filing | |
| $117.16 | 2,212 | Director | 60,179 | 2024-06-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 44,467,463 | $5,517,967,483 | 0.12% | |
| 2. | 32,726,186 | $4,060,992,422 | 0.1% | |
| 3. | 16,520,313 | $2,050,005,640 | 1.69% | |
| 4. | 16,198,598 | $2,010,084,026 | 0.09% | |
| 5. | 15,296,032 | $1,898,085,347 | 0.46% |
News See All
DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Call Transcript
DexCom, Inc. beats earnings expectations. Reported EPS is $0.32, expectations were $0.27. DexCom, Inc.
14 Best 52-Week High Stocks To Invest In Now
This article delves into the examination of the 14 best 52-week high stocks to buy now.
5 Best Weight Loss Drug Stocks to Buy Now
In this piece, we will take a look at the five best weight loss drug stocks to buy now.
Should You Hold DexCom (DXCM)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine-related diseases.
Here's What Happened to Dexcom (DXCM) Stock in Q4
Brown Capital Management, an investment management company, released its “The Brown Capital Management Mid Company Fund” fourth quarter 2023 investor letter.
14 Best Medical Device Stocks To Buy Now
In this article, we will discuss the 14 Best Medical Device Stocks To Buy Now.
Should You Hold DexCom (DXCM) for the Long Term?
Next Century Growth Investors, LLC, an investment Management Company, released its “SMID Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
Here’s Why DexCom (DXCM) Outperformed in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Billionaire Hedge Funds
